AstraZeneca (OSTO:AZN) Change In Working Capital : kr-9,095 Mil (TTM As of Mar. 2025)

View and export this data going back to 1999. Start your Free Trial

What is AstraZeneca Change In Working Capital?

AstraZeneca's change in working capital for the quarter that ended in Mar. 2025 was kr-4,317 Mil.

AstraZeneca's change in working capital for the fiscal year that ended in Dec. 2024 was kr-9,810 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

AstraZeneca Change In Working Capital Historical Data

The historical data trend for AstraZeneca's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Change In Working Capital Chart

AstraZeneca Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Working Capital

Get a 7-Day Free Trial

3,019.08

18,370.08

38,990.15

3,077.28

-9,809.61

AstraZeneca Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Working Capital	Get a 7-Day Free Trial															-4,737.14	-1,352.82	419.39	-3,844.75	-4,316.57

AstraZeneca Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-9,095 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

AstraZeneca Change In Working Capital Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (OSTO:AZN) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:USA AZN1:Mexico AZNN:Mexico AZNl:UK AZN:UK ZEG:Germany A1ZN34:Brazil AZNA:Austria AZN:Argentina

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.